Microdialysis-Based 48-Hour Continuous Glucose Monitoring with GlucoDay<sup>™</sup>: Clinical Performance and Patients' Acceptance

Kubiak, Thomas; Wörle, Birgit; Kuhr, B.; Nied, I.; Gläsner, G.; Hermanns, Norbert; Kulzer, Bernd; Haak, Thomas

doi:10.1089/dia.2006.8.570

Cited by 34 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, microperfusion was applied by using a standard 18-gauge cannula in subcutaneous adipose tissue of the periumbilical region, an insertion site that is preferably used also for the application of techniques for subcutaneous glucose monitoring (1,3,4,15,30). It is likely that, similar to the situation in this study, subcutaneous glucose sensors and microdialysis-based glucose monitoring techniques also cause an inflammatory response of the tissue.…”

Section: Discussionmentioning

confidence: 94%

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Pachler

Ikeoka²,

Plank³

et al. 2007

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Inflammatory cytokines released from adipose tissue play an important role in different pathological processes. In the present study, we investigated the inflammatory cytokine response of human subcutaneous adipose tissue (SAT) by applying the open-flow microperfusion technique. Four standard 18-gauge microperfusion catheters were inserted into periumbilical SAT of eight healthy male volunteers [29 Ϯ 3 yr, BMI 24.3 Ϯ 1.9 (mean Ϯ SD)]. SAT probe effluents were collected at 60-min intervals for 8 h after catheter insertion. Different perfusion fluids were used to measure the local effect of insulin and/or glucose on the cytokine response. SAT probe effluents were analyzed for IL-1␤, IL-6, CXCL8 (IL-8), and TNF-␣. SAT concentrations of IL-1␤ increased 100-fold from 1.0 Ϯ 0.2 pg/ml (mean Ϯ SE) to 101.5 Ϯ 23.2 pg/ml (P Ͻ 0.001) after 8 h. A 130-fold increase was observed for CXCL8, from 49 Ϯ 29 to 6,554 Ϯ 1,713 pg/ml (P Ͻ 0.001). Furthermore, a 20-fold increase of IL-6 was observed within the first 5 h (from 159 Ϯ 123 to 3,554 Ϯ 394 pg/ml; P Ͻ 0.001), and a significant decline to 2,154 Ϯ 216 pg/ml (P Ͻ 0.01) was seen thereafter. Finally, TNF-␣ increased from 1.4 Ϯ 0.6 to 2.5 Ϯ 0.5 pg/ml (P Ͻ 0.05) in hour 2 and remained stable thereafter. Local administration of insulin exerted a stimulatory effect on the inflammatory response of IL-6. In conclusion, SAT exerts a highly reproducible and consistent proinflammatory cytokine response after minimally invasive trauma caused by the insertion of a catheter in humans.

show abstract

Section: Discussionmentioning

confidence: 94%

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Pachler

Ikeoka²,

Plank³

et al. 2007

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…67,325, The SCGM1 system of Roche Diagnostics, Mannheim, Germany, 354 and the GlucoDay system of A. Menarini IFR S.r.l, Florence, Italy, 331,345,346,[349][350][351][352]355 are microdialysisbased. Their microdialysis fibers are implanted in the abdominal adipose-tissue, their fluid flowing to an external amperometric H 2 O 2 -electrooxidizing GOx-utilizing sensor.…”

Section: Systems With Subcutaneous Ultrafiltration and Microdialysis mentioning

confidence: 99%

Electrochemical Glucose Sensors and Their Applications in Diabetes Management

2008

View full text Add to dashboard Cite

About 6,000 peer reviewed articles have been published on electrochemical glucose assays and sensors, of which 700 were published in the 2005-2006 two-year period. Their number makes a full review of the literature, or even of the most recent advances, impossible. Nevertheless, this review should acquaint the reader with the fundamentals of the electrochemistry of glucose and provide a perspective of the evolution of the electrochemical glucose assays and monitors helping diabetic people, who constitute about 5% of the world's population. Because of the large number of diabetic people, no assay is performed more frequently than that of glucose. Most of these assays are electrochemical. The reader interested also in nonelectrochemical assays used in, or proposed for, the management of diabetes is referred to a 2007 review of Kondepati and Heise. 1 Adam Heller was born in 1933. Surviving the Holocaust, he arrived in Israel in 1945. He received his M.Sc. in Chemistry and Physics in 1957, then his PhD in Organic Chemistry in 1961 from Ernst David Bergman at the Hebrew University in Jerusalem. He postdoced at UC Berkeley (1962-3) and at Bell Laboratories . At GTE Labs (1964-1975 he built the first Nd 3+ liquid laser and, with J. J. Auborn, the still worldwide used Li/SOCl 2 battery. At Bell Labs (1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985)(1986)(1987)(1988) he designed the first >10% efficient electrochemical solar cells and the first >10% efficient hydrogengenerating solar-powered photoelectrode. He also headed Bell Labs' Electronic Materials Research Department (1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985)(1986)(1987)(1988), which developed part of the high density chip interconnection technology underlying the miniaturization of portable electronic devices. He was appointed to the Ernest Cockrell Sr. Chair in Engineering of the University of Texas at Austin in 1988, and in 2001 became one of UT's first Research Professors. At UT he pioneered the electrical wiring of enzymes. In 1996 he cofounded with his son Ephraim Heller TheraSense Inc., now part of Abbott Diabetes Care, to improve the lives of diabetic people. The company introduced in 2000 the blood sugar monitor FreeStyle, a thin-layer microcoulometer utilizing only 300 nL of blood, so little that it was, for the first time, painlessly obtained. In 2007 it provided for more than 1 billion painless glucose assays. After alleviating the pain of diabetes monitoring, FreeStyle Navigator, based on the electrical wiring of glucose oxidase, introduced in 2007 in Europe and Israel and in 2008 in the U.S., removed the worry of diabetic people by continuously monitoring their glucose levels. Heller aims his work at alleviating suffering through bioelectrochemistry.

show abstract

“…Consequently, it requires only one calibration per day and has less sensor drift than the CGMS system. In clinical trials, sensor accuracy is acceptable [89]. Using the Menarini GlucoDay system (Menarini Diagnostics, Florence, Italy), 95.5% of values are within areas A and B of the Clarke error grid with r = 0.9 [90].…”

Section: Microdialysismentioning

confidence: 99%

Glucose sensors: a review of current and emerging technology

et al. 2009

View full text Add to dashboard Cite

Glucose monitoring technology has been used in the management of diabetes for three decades. Traditional devices use enzymatic methods to measure glucose concentration and provide point sample information. More recently continuous glucose monitoring devices have become available providing more detailed data on glucose excursions. In future applications the continuous glucose sensor may become a critical component of the closed loop insulin delivery system and, as such, must be selective, rapid, predictable and acceptable for continuous patient use. Many potential sensing modalities are being pursued including optical and transdermal techniques. This review aims to summarize existing technology, the methods for assessing glucose sensing devices and provide an overview of emergent sensing modalities.

show abstract

Microdialysis-Based 48-Hour Continuous Glucose Monitoring with GlucoDay^™: Clinical Performance and Patients' Acceptance

Abstract: Satisfactory to good performance of the GlucoDay monitor was observed, indicating the device to be suitable for routine clinical use. In particular, however, the discomfort experienced during wearing requires further improvements in its usability.

Cited by 34 publications

References 4 publications

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Electrochemical Glucose Sensors and Their Applications in Diabetes Management

Glucose sensors: a review of current and emerging technology

Contact Info

Product

Resources

About

Microdialysis-Based 48-Hour Continuous Glucose Monitoring with GlucoDay™: Clinical Performance and Patients' Acceptance

Abstract: Satisfactory to good performance of the GlucoDay monitor was observed, indicating the device to be suitable for routine clinical use. In particular, however, the discomfort experienced during wearing requires further improvements in its usability.

Cited by 34 publications

References 4 publications

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans

Electrochemical Glucose Sensors and Their Applications in Diabetes Management

Glucose sensors: a review of current and emerging technology

Contact Info

Product

Resources

About

Microdialysis-Based 48-Hour Continuous Glucose Monitoring with GlucoDay^™: Clinical Performance and Patients' Acceptance